Astria Therapeutics, Inc.
Clinical-stage biopharma developing therapies for allergic and immunologic diseases.
ATXS | US
Overview
Corporate Details
- ISIN(s):
- US04635X1028
- LEI:
- Country:
- United States of America
- Address:
- 22 BOSTON WHARF ROAD, 2210 BOSTON
- Website:
- https://astriatx.com/
- Sector:
- Manufacturing
Description
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Astria Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Astria Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Astria Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
